Blade Therapeutics nabs $45 mln Series B
South San Francisco-based Blade Therapeutics, a biopharmaceutical company that treats fibrotic disease, has raised $45 million in Series B funding. Deerfield Management led the round with participation from other investors that included Pfizer Venture Investments, MPM Capital, Osage University Partners and Bristol-Myers Squibb. In conjunction with the funding, Dr. William Slattery and Cameron Wheeler of Deerfield Management and Dr. Elaine Jones of Pfizer Venture Investments have been added to Blade's board of directors.
16 June 2016•1 min read
